Sign Up to like & get
recommendations!
0
Published in 2025 at "Gastroenterology"
DOI: 10.1016/s0016-5085(25)01901-8
Abstract: OBJECTIVES Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in EoE…
read more here.
Keywords:
treatment;
response thresholds;
response;
eosinophilic esophagitis ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Scandinavian journal of gastroenterology"
DOI: 10.1080/00365521.2023.2194009
Abstract: BACKGROUND Response evaluation after induction therapy with ustekinumab (UST) in Crohn's disease (CD) is important for decisions on maintenance therapy. We aimed to assess the potential of fecal calprotectin (FC) levels to predict endoscopic response…
read more here.
Keywords:
endoscopic response;
therapy;
crohn disease;
fecal calprotectin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diseases of the Esophagus"
DOI: 10.1093/dote/doy089.ps02.086
Abstract: To investigate the association between endoscopic response evaluation of neoadjuvant chemotherapy (NAC) with pathological response and survival in patients with esophageal squamous cell carcinoma (ESCC). We retrospectively reviewed the medical records of patients with the…
read more here.
Keywords:
response;
endoscopic response;
pathological response;
response evaluation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1016
Abstract: It is unclear whether ustekinumab (UST) concentrations can predict the clinical course of inflammatory bowel disease (IBD) and guide treatment algorithms during the induction phase. The aim of our study was to assess the association…
read more here.
Keywords:
week;
disease;
ust concentrations;
remission ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izaa253
Abstract: BACKGROUND Gut microbiota dysbiosis is associated with the occurrence and development of Crohn disease (CD). Currently, infliximab (IFX) is used more and more to treat CD; however, gut microbiota alterations during IFX therapy are variable…
read more here.
Keywords:
week;
response;
microbiota;
clinical endoscopic ... See more keywords